Compare NXDT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | ZNTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.8M | 289.0M |
| IPO Year | 2006 | 2020 |
| Metric | NXDT | ZNTL |
|---|---|---|
| Price | $5.54 | $3.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 182.5K | ★ 995.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,965,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $2.55 | $1.21 |
| 52 Week High | $5.95 | $6.95 |
| Indicator | NXDT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 41.47 |
| Support Level | $4.43 | $3.75 |
| Resistance Level | $5.62 | $4.00 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 80.60 | 50.00 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.